The University of Southampton
University of Southampton Institutional Repository

Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.

Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.
Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.
Mesothelioma is increasing worldwide. However there is no approved therapy in the second-line setting. Vinorelbine exhibits promising activity, however there has been no randomised evaluation or validation of biomarkers to support patient stratification. We have recently reported that BRCA-1 is an essential regulator of mesothelioma sensitivity to vinorelbine, and its expression is lost in approximately 38%1. The Cancer Research UK VIM trial is to be sponsored by the University of Leicester in collaboration with the Wales Cancer Clinical Trials Unit.
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Fennell, D.
84b37c3c-f082-49c4-879d-267f4928097a
Casbard, A.
a5459533-54d6-4ca2-b746-8518afa0c914
Nixon, L.
14cb3daf-d29a-4734-9e18-1b891e8c2fcc
Lester, J.
37d845f6-1d28-4b2b-8535-b938a491396e
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Fennell, D.
84b37c3c-f082-49c4-879d-267f4928097a
Casbard, A.
a5459533-54d6-4ca2-b746-8518afa0c914
Nixon, L.
14cb3daf-d29a-4734-9e18-1b891e8c2fcc
Lester, J.
37d845f6-1d28-4b2b-8535-b938a491396e

Griffiths, Gareth, Fennell, D., Casbard, A., Nixon, L. and Lester, J. (2012) Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.

Record type: Conference or Workshop Item (Poster)

Abstract

Mesothelioma is increasing worldwide. However there is no approved therapy in the second-line setting. Vinorelbine exhibits promising activity, however there has been no randomised evaluation or validation of biomarkers to support patient stratification. We have recently reported that BRCA-1 is an essential regulator of mesothelioma sensitivity to vinorelbine, and its expression is lost in approximately 38%1. The Cancer Research UK VIM trial is to be sponsored by the University of Leicester in collaboration with the Wales Cancer Clinical Trials Unit.

Full text not available from this repository.

More information

Published date: 2012

Identifiers

Local EPrints ID: 413097
URI: http://eprints.soton.ac.uk/id/eprint/413097
PURE UUID: a1129009-4263-4905-a196-46d0ecb9e2b8
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021

Catalogue record

Date deposited: 15 Aug 2017 16:30
Last modified: 30 Jan 2020 01:40

Export record

Contributors

Author: D. Fennell
Author: A. Casbard
Author: L. Nixon
Author: J. Lester

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×